180 Life Sciences Corp. — Q1 2022 Form 10-Q
Filing identity: The request metadata names FORUM MARKETS Inc., but the supplied filing is for 180 Life Sciences Corp. (NASDAQ: ATNF; warrants: ATNFW). This summary reflects the supplied filing, for the three months ended March 31, 2022, filed May 16, 2022.
Business context and reporting period
180 Life Sciences is a clinical-stage biotechnology company developing therapeutics for chronic pain, inflammation, fibrosis and related conditions. Its platforms include fibrosis/anti-TNF, CBD derivatives and alpha-7 nicotinic acetylcholine receptor programs. The company reported no revenue and remains dependent on external financing.
Financial results and liquidity
| Metric | Q1 2022 | Q1 2021 / comparison |
|---|---|---|
| Revenue | None reported | None reported |
| Operating expenses | $3.68 million | $2.95 million; up 25% |
| Research and development | $0.71 million, including related-party expense | $0.37 million; increase mainly reflected consulting, payroll, Oxford University work, anti-TNF costs and stock compensation |
| General and administrative | $2.97 million, plus $5,261 related-party expense | $2.54 million, plus $39,120 related-party expense; non-related-party increase primarily reflected patent and insurance costs |
| Operating loss | $3.68 million | $2.95 million |
| Net income (loss) | $1.56 million | $(16.20) million |
| Basic and diluted EPS | $0.05 | $(0.58) |
| Cash used in operations | $2.07 million | $6.33 million |
| Cash and cash equivalents | $5.67 million at March 31, 2022 | $8.22 million at December 31, 2021 |
| Working capital deficit | $6.12 million | $8.50 million at December 31, 2021 |
Q1 net income was driven primarily by a $5.23 million non-cash gain from a decrease in the fair value of derivative liabilities, not by operating revenue. The company reported a $728,081 foreign-currency translation loss in other comprehensive income. Profit margins are not meaningful given the absence of revenue.
Total liabilities were $18.77 million, including $9.99 million of current derivative liabilities and $1.34 million of loans payable ($1.30 million current, including related-party loans). Stockholders’ equity was $40.90 million. Financing activities used $515,419, mainly for loan repayments; there were no financing transactions during the quarter. The filing reports a minimum monthly cash requirement of approximately $800,000 and estimated contractual and other cash requirements of $7.1 million for 2022 and $33.4 million for 2023–2026.
Material changes versus the prior comparable period
- Net results swung to income from a substantial loss, mainly because the prior-year period had a $13.23 million derivative fair-value loss, while Q1 2022 recorded a $5.23 million gain. These changes are non-cash and market-sensitive.
- Operating expenses rose $732,766, or about 25%, while operating loss widened by the same amount.
- Cash used in operations fell to $2.07 million from $6.33 million. The company had $10.73 million of net equity-offering proceeds in Q1 2021 but none in Q1 2022.
- Derivative liabilities declined to $9.99 million from $15.22 million at year-end 2021, largely due to fair-value remeasurement. Cash declined by approximately $2.56 million during the quarter.
Outlook, risks, contingencies and unusual items
- Going concern and funding: Management says substantial doubt exists about the company’s ability to continue as a going concern for one year after issuance. It expects continued operating losses and significant R&D spending, and says additional financing is necessary. No credit facility or committed capital source was reported. Failure to raise funds could force reduced development activity or cessation of operations. Future equity or debt financing may be dilutive or on unfavorable terms.
- Clinical and business risks: The Phase 2b Dupuytren’s Contracture trial follow-up and analysis were delayed by COVID-19; top-line results were announced in December 2021 and published in a peer-reviewed journal on April 29, 2022. Clinical success, regulatory approval, manufacturing and commercialization remain uncertain. Management expects R&D and other operating expenses to increase; no revenue or profitability timeline is provided.
- Legal matters: Litigation includes the company’s claims against former KBL executives (seeking more than $11.29 million), a dispute with Tyche Capital (company claim of $6.78 million), and claims against the Bauer defendants seeking multiple amounts. Outcomes are uncertain. Separately, a court ordered advancement of certain legal fees for Dr. Krauss; the company paid $975,121 into escrow on April 29, 2022, disputes some charges and is seeking insurance reimbursement, with no assurance of coverage.
- Compensation and funding condition: April 2022 amendments reduced or deferred certain executive compensation; deferred amounts are generally tied to a funding determination requiring at least $15 million raised. These were subsequent events, not Q1 cash flows.
- Controls: Disclosure controls were deemed ineffective as of March 31, 2022. Continuing material weaknesses include a lack of a fully integrated financial consolidation/reporting system and ineffective review controls over stock compensation and payroll expense classification. Management planned remediation, including improved processes and possible automated consolidation software.
- Other risks: The filing cites potential goodwill impairment, securities-registration risks, COVID-19 effects on operations and access to capital, and possible impacts from the Russia-Ukraine conflict and broader market disruption.
Important facts for investors to verify
- Confirm the intended issuer: the supplied document is 180 Life Sciences Corp., not FORUM MARKETS Inc.
- Assess cash runway and financing needs against the stated approximately $800,000 monthly cash requirement, working-capital deficit and going-concern warning.
- Separate operating performance from the non-cash derivative-liability gain; review warrant terms and the sensitivity of reported earnings to fair-value changes.
- Track clinical-program progress, regulatory milestones and any further COVID-related or other trial delays.
- Monitor litigation developments, the $975,121 legal-fee advancement and any insurance recovery or additional accruals.
- Review remediation of the disclosed material weaknesses and confirm future filings address them.
- Reconcile cash figures: the balance sheet and cash-flow statement show December 31, 2021 cash of $8,224,508, while the MD&A states $8,244,508.